fluorouracil + leucovorin calcium + semaxanib

This is a combination regimen composed of three drugs: **fluorouracil**, an antimetabolite that inhibits thymidylate synthase and thus DNA synthesis; **leucovorin calcium**, a reduced folate that enhances the inhibition of thymidylate synthase by fluorouracil; and **semaxanib (SU5416)**, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. This regimen has been studied as a chemotherapy and antiangiogenic therapy for metastatic colorectal cancer, though a phase III trial found no benefit and increased toxicity for semaxanib added to the fluorouracil/leucovorin backbone compared to fluorouracil/leucovorin alone[3]. Fluorouracil and leucovorin are established drugs for a range of solid tumors, while semaxanib is an experimental VEGFR-1/2 inhibitor.

Other names

fluorouracil + leucovorin calcium + semaxanib5-FU + LV + semaxanib